CONVERSION PRICE ADJUSTMENT AGREEMENTConversion Price Adjustment Agreement • November 27th, 2020 • Inspyr Therapeutics, Inc. • Pharmaceutical preparations • New York
This conversion price adjustment agreement (“Agreement”) dated as of November 25, 2020 is by and among Sabby Healthcare Master Fund, Ltd., Sabby Volatility Warrant Master Fund, Ltd. (collectively, “Sabby”) and Inspyr Therapeutics, Inc., a Delaware corporation (the “Company”). Any terms not specifically defined herein shall have the definition ascribed to them in the Securities Purchase Agreement, dated as of December 13, 2018, by and among the Company and Sabby.
